NATALEE
What it tests: Prognostic and predictive impact of baseline gene expression (EXP) in the NATALEE trial of adjuvant (ADJ) ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in HR+/HER2− early breast cancer (EBC)
Videos
monarchEDESTINY-Breast05DESTINY-Breast11and 2 moreDr. Elisa AgostinettoBreast cancer: the picks from Berlin
Dr. Elisa Agostinetto. Expert pick. ESMO 2025.
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.